Trial Profile
SHR-1316, a Novel Anti-PD-L1 Antibody, in Combination With Irinotecan Liposome and Fluorouracil in Patients With Esophageal Squamous Cell Cancer: a Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Adebrelimab (Primary) ; Fluorouracil (Primary) ; Irinotecan (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 Nov 2018 New trial record